QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

BLTE

QT61Belite Bio, Inc
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
146.12
-2.22-1.50%
OverviewShort InterestFilings
BLTEQT61Belite Bio, Inc·NASDAQ
OverviewShort InterestFilings
146.12-1.50%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own2.54%
Shs Outstand40.09M
Perf Week6.77%
Market Cap5.95BForward P/E153.12EPS next Y0.95Insider Trans-0.11%Shs Float-Perf Month4.60%
Enterprise Value5.59BPEG1.22EPS next Q-0.73Inst Own-Short Float-Perf Quarter-8.24%
Income-90977200.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y-2.02%
Sales-P/B7.68EPS next Y129.06%ROA-11.57%Short Interest-Perf YTD-8.65%
Book/sh2.24P/C-EPS next 5Y-ROE-26.70%52W High200.00 -26.94%Perf Year149.56%
Cash/sh2.20P/FCF-EPS past 3/5Y-ROIC-13.15%52W Low56.10 160.46%Perf 3Y-
Dividend Est.-EV/EBITDA-58.52Sales past 3/5Y-Gross Margin0.00%Volatility3.44% 4.19%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-58.47%Oper. Margin0.00%ATR (14)8.20Perf 10Y-
Dividend Ex-Date-Quick Ratio50.02Sales Y/Y TTM-Profit Margin0.00%RSI (14)51.34Recom2.00
Dividend Gr. 3/5Y-Current Ratio50.02EPS Q/Q24.44%SMA203.11%Beta0.87Target Price208.00
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA50-3.81%Rel Volume1.40Prev Close148.34
Employees25LT Debt/Eq0.01EarningsAug 10SMA2005.61%Avg Volume181.65KPrice146.12
IPO DateApr 29, 2022Option/ShortYes / YesEPS/Sales Surpr.43.33% -Net Debt/EBITDA3.69Volume254,471Change-1.50%
Analyst Ratings
DateActionAnalystRatingTarget
May-26-26ReiteratedMizuho Securities$223 → $215
May-22-26ReiteratedTruist Financial$217
Mar-04-26ReiteratedH.C. Wainwright$185 → $200
Mar-03-26ReiteratedNeedham$217
Feb-19-26ReiteratedMizuho Securities$194 → $223
Jan-06-26InitiatedMorgan StanleyOverweight$191
Dec-03-25ReiteratedBTIG$187
Dec-02-25ReiteratedMaxim GroupBuy$140 → $200
Dec-02-25ReiteratedMizuho Securities$105 → $194
Dec-02-25UpgradeMizuhoNeutral → Outperform
Latest News
Jun-15-26
Jun-15-2607:47AM
HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price TargetBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit
000
Selling, General and Administrative Excl. Other39107
Research and Development453025
Other Operating Expense000
Operating Income-84-40-32
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-7-40
Net Income Before Taxes-78-36-32
Income Taxes
000
Consolidated Net Income-78-36-32
Net Income From Continuing Operations-78-36-32
Net Income-78-36-32
EPS (Recurring)-2.31-1.18-1.19
EPS (Basic, Before Extraordinaries)-2.31-1.18-1.19
EPS (Diluted)-2.31-1.18-1.19
EBITDA-77-36-31
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding343127
Market Capitalization5,439——
Operating Lease Expense
———
Insider Trading Volume
$156.98$141.60$126.21$110.82$95.44● Close Price0.00M1.24M2.47M3.71M4.94MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Scholl Hendrik PeterChief Medical OfficerJun 16 '26Sale140.5710,0001,405,72925,000Jun 17 12:00 AM
MATA NATHAN L.Chief Scientific OfficerMay 07 '26Sale153.21666102,0390May 08 12:00 AM
MATA NATHAN L.Chief Scientific OfficerMay 06 '26Sale153.841,000153,840666May 07 12:00 AM
MATA NATHAN L.Chief Scientific OfficerMay 05 '26Sale155.501,000155,5031,666May 06 12:00 AM
MATA NATHAN L.Chief Scientific OfficerMay 04 '26Sale155.641,000155,6352,666May 05 12:00 AM
MATA NATHAN L.Chief Scientific OfficerMay 01 '26Sale155.781,000155,7783,666May 04 12:00 AM
MATA NATHAN L.Chief Scientific OfficerApr 30 '26Sale156.971,000156,9724,666May 01 12:00 AM
MATA NATHAN L.Chief Scientific OfficerApr 29 '26Sale155.821,000155,8165,666Apr 30 12:00 AM
MATA NATHAN L.Chief Scientific OfficerApr 28 '26Sale159.161,000159,1626,666Apr 29 12:00 AM
MATA NATHAN L.Chief Scientific OfficerApr 27 '26Sale162.641,000162,6427,666Apr 28 12:00 AM
MATA NATHAN L.Chief Scientific OfficerApr 24 '26Sale159.561,000159,5568,666Apr 27 12:00 AM
MATA NATHAN L.Chief Scientific OfficerApr 23 '26Sale166.281,000166,2839,666Apr 24 12:00 AM
MATA NATHAN L.Chief Scientific OfficerApr 22 '26Sale170.381,000170,38410,666Apr 23 12:00 AM
MATA NATHAN L.Chief Scientific OfficerApr 21 '26Sale166.001,000166,00111,666Apr 22 12:00 AM
MATA NATHAN L.Chief Scientific OfficerApr 20 '26Sale163.591,000163,59512,666Apr 21 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR